Razoxane oral - Tryp Therapeutics
Alternative Names: TRP-1001Latest Information Update: 01 Feb 2023
At a glance
- Originator TRYP Therapeutics
- Class Cytostatics; Piperazines
- Mechanism of Action Type II DNA topoisomerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Discontinued Soft tissue sarcoma
Most Recent Events
- 01 Feb 2023 Discontinued - Phase-II for Soft tissue sarcoma (Metastatic disease) in Canada (PO)
- 18 Aug 2021 Chemical structure information added
- 29 Dec 2020 Razoxane oral - Tryp Therapeutics is available for licensing as of 29 Dec 2020. https://www.tryptherapeutics.com/